<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371329</url>
  </required_header>
  <id_info>
    <org_study_id>15-003524</org_study_id>
    <nct_id>NCT03371329</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage</brief_title>
  <official_title>Safety and Feasibility of Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to develop mesenchymal stem cell therapy for treatment of
      acute spontaneous hemorrhagic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall clinical development strategy of this project is to conduct this Phase I dose
      escalation study entitled &quot;A Pilot Study to Evaluate the Safety and Feasibility of
      Mesenchymal Stem Cells Therapy in Patients with Recent Intracerebral Hemorrhage&quot;. This study
      will be performed under this current IND application and will be limited to the proposed 12
      subjects (3 IV and 1 IT dose groups).

      In this application the investigators are proposing to evaluate safety and feasibility of
      allogeneic, bone marrow (BM) derived mesenchymal stem cells (MSC) to induce
      neuroregeneration, improve neurological function and alleviate inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Anticipated">December 12, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Number of adverse events at each Mesenchymal Stem Cell (MSC) dose and following infusions up to one year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in neurological function test</measure>
    <time_frame>Pre infusion and post-infusion days 1, 2, 3, 7, 30, 90, 180</time_frame>
    <description>The NIH Stroke Scale will be used to assess stroke-related neurologic deficits. A trained observer rates the patient's ability to perform tasks and answer questions. Ratings for each item are scored with 3 to 5 grades with 0 as normal.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hemorrhagic Stroke</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Group 1 MSC dose .5 x 10^6/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for 3 participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 MSC dose 1 x 10^6/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of MSC (mesenchymal stem cell) dose 1 x 10^6/kg for next 3 participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 MSC dose 2 x 10^6/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of MSC (mesenchymal stem cell) dose 2 x 10^6/kg for next 3 participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 MSC dose 0.5 x 10^6/kg I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraventricular infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for final 3 participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC</intervention_name>
    <description>bone marrow derived cultured MSC (mesenchymal stem cell)</description>
    <arm_group_label>Group 1 MSC dose .5 x 10^6/kg IV</arm_group_label>
    <arm_group_label>Group 2 MSC dose 1 x 10^6/kg IV</arm_group_label>
    <arm_group_label>Group 3 MSC dose 2 x 10^6/kg IV</arm_group_label>
    <arm_group_label>Group 4 MSC dose 0.5 x 10^6/kg I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Age range: 18 years or older

          -  Gender: Male or female

          -  Acute spontaneous supratentorial ICH documented by head CT with ICH Score between 2 -
             4 inclusive

          -  Stable ICH hematoma volume 60mL or less as measured by ABC2 method by 24-72hrs

          -  Ability to be enrolled within 72 hours of onset of stroke symptoms

          -  Ability to provide written personal or surrogate consent. Only subjects who have
             signed the ICF will be enrolled into the study. The ICF will include elements required
             by Mayo IRB and FDA in US 21CFR50.

          -  Subject must have adequate renal function; creatinine &lt;1.5g/dl.

          -  Subject must be available for all specified assessments at the study site through the
             completion of the study.

          -  Subject must provide written ICF and authorization for use of and disclosure of PHI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abba C Zubair</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Braddock</last_name>
      <phone>904-953-6012</phone>
      <email>braddock.lindsay@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Abba C. Zubair, M.D., Ph.D.</investigator_full_name>
    <investigator_title>medical Director</investigator_title>
  </responsible_party>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>stroke</keyword>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

